Pharma Roundup: Generics at Pfizer, Risk-taking at Lilly, and More

(MoneyWatch)  Pfizer embraces generics -- The company already produces generics through its Greenstone unit, holding about 4% of the global generics market, but wants to play a much larger role. Pfizer is evidently staking its enhanced plan on injectables and new formulations of existing products. [Source: WSJ Health Blog]
Lilly CEO on risky bets: "This is what we do every day" -- CEO John Lechleiter contextualized Lilly's recent acquisition of ImClone--and the pipeline he hopes will rake in profit--within the everyday risks of R&D operations, during an interview with the Indianapolis Star. According to Lechleiter, doing nothing would have been much riskier than the expensive purchase. He also alluded to past errors of judgment on products like Cymbalta and Evista. [Source: PharmaGossip]

Boehringer, Pfizer/BMS, Bayer/J&J: new blood clot meds coming soon -- Competition is tight in the race to put out improved blood clot treatments, a market the Wall Street Journal estimates will be worth $20 billion by 2016. All three projects (Boehringer Ingelheim, Pfizer partnered with Bristol-Myers Squibb, Bayer partnered with Johnson & Johnson) are in late-stage clinical trials. [Source: Pharmalot]

BMS decreasing international ops? -- Bristol-Myers Squibb is putting its Pakistan operations up for sale. Considering that BMS is also pulling out of Egypt, it appears that emerging markets are not part of their current strategy. [Source: FiercePharma]